- 24 min ago Amazon Great Indian Sale 2021: Up to 60% Off On Home And Kitchen Essentials
- 1 hr ago Kubbra Sait And Deepika Padukone Can Give You Cues On How To Look Cool And Ace The Street-Style Look
- 3 hrs ago Expert Article: The Indian Perception On Cosmetic Surgery
- 4 hrs ago Your Denim Edit Ft. Nushrratt Bharuccha And Sara Ali Khan
- Movies Bigg Boss 15: Afsana Khan's Fiance Reacts To Salman Reprimanding Her; Feels These 2 Can Backstab Her
- Technology Xiaomi 12 Series Tipped To Feature 50MP Triple Cameras; Expected Launch, Features
- News Priyanka Gandhi stopped from meeting family of man who died in police custody
- Sports Newcastle United part ways with Steve Bruce following takeover
- Finance Indian Gold Rates Down By A Tad Before Diwali, Quoted At Rs. 46,490, On Oct 20
- Education Kerala SET January 2022 Registration Opens. Check KSET Exam Date, Admit Card And Eligibility Details Here
- Automobiles Limited-Edition Toyota Innova Crysta Launched In India: Comes With HUD, 360-Degree Camera, And More Features
- Travel Tamil Nadu's Ten Best Winter Destinations
Bharat Biotech, which completed the Phase 2/3 trials of Covid-19 vaccine Covaxin for use in children under 18 years of age, has submitted the data to the Central Drugs Standard Control Organisation for its verification and subsequent approval for Emergency Use Authorisation for the jab, company sources said on Wednesday.
"Covaxin clinical trial data of 2-18 years age group has been submitted to CDSCO. This is feasible due to the safety of the manufacturing platform and empirical evidence from Phase 1,2 and 3 clinical trials in adults," sources told PTI.
Chairman and Managing Director of Bharat Biotech International Ltd, Krishna Ella, had said on September 21 that the Paediatric Covaxin completed phase 2/3 trials with about 1,000 subjects and the data analysis was going on.
As part of the Phase II/III trial, the two-dose Covaxin was administered with 28 days apart.
"We will be submitting the data (to the regulator) by next week," he had said.
He also had said that Phase 2 trials of an intranasal vaccine to prevent Covid-19 were going on and expected to be over in October.
If approved, Covaxin will be the first Covid-19 vaccine that can be administered to children in India.